Second, the group with surveillance contained relatively more MLH1/MSH2/EpCAM carriers, albeit not significant, who have a higher risk to develop endometrial carcinoma,31 usually have an earlier endometrial carcinoma age of onset,32 and were historically advised to enroll in a gynaecological surveillance program from the age of 30–35 years old (no time-trend bias). The gene discussed is EPCAM; the disease is endometrial carcinoma.